

Memory Pharmaceuticals

[View the current Memory Pharmaceuticals Page on BioPortfolio.com](http://www.bioportfolio.com/bioporporate/6931-Memory+Pharmaceuticals.html)

(<http://www.bioportfolio.com/bioporporate/6931-Memory+Pharmaceuticals.html>)

Contact Details:

100 Philips Parkway

Montvale

NJ

07645

United States of America

Tel: (201) 802-7100

Fax: (201) 802-7190

Email: ir@memorypharma.com

Memory Pharmaceuticals is a leading neuropharmaceutical drug development company working in the field of learning and memory disorders. Memory Pharmaceutical' technology platform is based on intellectual property developed by Nobel Laureate Eric Kandel, M.D., the scientific founder of the Company. They established a proprietary COGNOSTICS™ technology platform, which consists of an array of state-of-the-art bioassays that evaluate the cell biological, physiological and behavioral aspects of drug effects within relevant memory pathways. The COGNOSTICS technology platform drives the critical steps involved in target validation, chemical hit and lead identification, lead optimization, and nomination of clinical development candidates.

Recent Publications by Memory Pharmaceuticals:



- [Assays for cyclic nucleotide-specific phosphodiesterases \(PDEs\) in the central nervous system \(PDE1, PDE2, PDE4, and PDE10\).](#)
*Since the identification of phosphodiesterase activity in brain tissue...*23rd May, 2008
Memory Pharmaceuticals Corp, Montvale, New Jersey, USA.- Curr Protoc Neurosci. 2007 Jan;Chapter 7:Unit 7.21. ([DOI Direct Link](#))
- [Assessment of learning and memory using the autoshaping of operant responding in mice.](#)
*This unit describes the use of an automated procedure for developing an...*13th May, 2008
Memory Pharmaceuticals, Montvale, New Jersey, USA.- Curr Protoc Neurosci. 2004 Feb;Chapter 8:Unit 8.5F. ([DOI Direct Link](#))
- [Efficacy of MEM 1003, a novel calcium channel blocker, in delay and trace eyeblink conditioning in older rabbits.](#)
*Eyeblink conditioning is a relatively simple form of associative learning...*1st June, 2007
Memory Pharmaceuticals Corp., Montvale, NJ, United States.- Neurobiol Aging. 2007

- May;28(5):766-73. Epub 2006 Apr 18. ([DOI Direct Link](#))
- [Hippocampal expression analyses reveal selective association of immediate-early, neuroenergetic, and myelinogenic pathways with cognitive impairment in aged rats.](#)
*Although expression of some genes is known to change during neuronal...*14th April, 2007
 Department of Functional Neuroscience, Memory Pharmaceuticals Corporation,- J Neurosci. 2007 Mar 21;27(12):3098-110. ([DOI Direct Link](#))
 - [Neurotensin receptor levels as a function of brain aging and cognitive performance in the Morris water maze task in the rat.](#)
*The present study evaluated whether neurotensin (NT) binding sites were...*9th December, 2006
 Memory Pharmaceuticals, 100 Philips Parkway, Montvale, NJ 07645, USA.- Peptides. 2006 Oct;27(10):2415-23. Epub 2006 Jul 26. ([DOI Direct Link](#))
 - [The slow afterhyperpolarization in hippocampal CA1 neurons covaries with spatial learning ability in aged Fisher 344 rats.](#)
*Rodents commonly exhibit age-related impairments in spatial learning...*3rd March, 2006
 Memory Pharmaceuticals Corporation, Montvale, New Jersey 07645, USA.- J Neurosci. 2005 Mar 9;25(10):2609-16. ([DOI Direct Link](#))
 - [Phosphodiesterase inhibitors for cognitive enhancement.](#)
*An effective treatment for age-related cognitive deficits remains an unmet...*21st December, 2005
 Memory Pharmaceuticals Corp., 100 Philips Parkway, Montvale, NJ 07645,- Curr Pharm Des. 2005;11(26):3329-34.
 - [Axel Unterbeck on memory, cognition and the development of CNS drugs. Interview by Steve Carney.](#)
*Rodents commonly exhibit age-related impairments in spatial learning...*2nd September, 2005
 Memory Pharmaceuticals, 100 Philips Parkway, Montvale, NJ 07645, USA.- Drug Discov Today. 2005 Feb 1;10(3):165-8. ([DOI Direct Link](#))
 - [Cerebrovasodilation evoked by stimulation of subthalamic vasodilator area and hypoxia depends upon the integrity of cortical neurons in the rat.](#)
*In Sprague-Dawley rats symmetrical sites of the parietal cortex were...*16th December, 2004
 Memory Pharmaceuticals Corp., 100 Philips Parkway, Montvale, NJ 07645,- Neurosci Lett. 2004 Sep 16;368(1):92-5. ([DOI Direct Link](#))
 - [Cloning and characterization of novel PDE4D isoforms PDE4D6 and PDE4D7.](#)
*We report here the cloning and characterization of two novel PDE4D...*7th May, 2004
 Discovery Research, Memory Pharmaceuticals Corp, 100 Philips Parkway,- Cell Signal. 2003 Sep;15(9):883-91.
 - [The emergence of behavioral pharmacology.](#)
*Beginning over five decades ago, a pioneering series of studies was...*1st May, 2004
 Memory Pharmaceuticals Corporation, 100 Philips Parkway, Montvale, NJ- Mol Interv. 2002 Dec;2(8):470-5. ([DOI Direct Link](#))
 - [Theta-frequency synaptic potentiation in CA1 in vitro distinguishes cognitively impaired from unimpaired aged Fischer 344 rats.](#)
*Hippocampal-dependent learning and memory deficits have been well...*26th November, 2002
 Memory Pharmaceuticals Corporation, Montvale, New Jersey 07645, USA.- J Neurosci. 2002 Nov 15;22(22):9932-40.

Press Releases on Memory Pharmaceuticals:

"As an Industry, We've Been too Focused on Regulatory Approval." Says Solvay Pharmaceuticals Eric Rambeaux at the Pharma Marketing Summit.	26th November, 2009		LONDON, November 26 /PRNewswire/ -- Rambeaux joined a host of other industry leaders at eyeforpharma's 9th annual Pharma Marketing Summit 2009 conference in Berlin, where several key themes
Onyx Pharmaceuticals Announces December 2009 Investor Events	25th November, 2009	Onyx Pharmaceuticals, Inc.	EMERYVILLE, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the company will host two investor events in December: ASH Briefing December 7, SAN DIEGO, Nov. 25 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that Barry D. Quart, Pharm.D., president and chief executive officer, will present at the Piper DELFT, The Netherlands and JOHANNESBURG, November 25 /PRNewswire/ -- iThemba Pharmaceuticals's service division and Pyxis Discovery announced today that they have signed a collaborative agreement
Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference	25th November, 2009	Ardea Biosciences, Inc.	
iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering	25th November, 2009		NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Cell/Tissue Culture Supplies - A Global Market Perspective http://www
Reportlinker Adds Cell/Tissue Culture Supplies - A Global Market Perspective	25th November, 2009	Reportlinker	

BioNews Results for Memory Pharmaceuticals



- [Memory Pharmaceuticals Corp-Detailed Product Pipeline - research report released](#)
PR inside: Nov 3 2009 1:05PM Matching: memory pharmaceuticals
- [Memory Pharmaceuticals Corp-Financial Company Report - research report released](#)

PR inside: Nov 2 2009 8:34AM Matching: memory pharmaceuticals

- [Harmonisation of ICD-11 and DSM-V: opportunities and challenges \[SPECIAL ARTICLE\]](#)

British Journal of Psychiatry: Nov 1 2009 5:22AM Matching: memory pharmaceuticals

- [Memory Pharmaceuticals Corp-Therapeutic Competitors - research report released](#)

PR inside: Oct 27 2009 6:59PM Matching: memory pharmaceuticals

Memory Pharmaceuticals Clinical Trials:



- [Safety and Efficacy of MEM 1003 Versus Placebo for the Treatment of Patients With Bipolar I Disorder](#)

Memory Pharmaceuticals Patents:



- 7585882- [Phosphodiesterase 4 inhibitors](#)
- 6699890- [Phosphodiesterase 4 inhibitors](#)
- 7087625- [Phosphodiesterase 4 inhibitors](#)
- 7153871- [Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs](#)
- 7205320- [Phosphodiesterase 4 inhibitors](#)
- 7235579- [Phosphodiesterase 4 inhibitors](#)
- 7244745- [Heterocyclic compounds, methods for the preparation thereof, and uses thereof](#)
- 7332486- [Phosphodiesterase 4 inhibitors](#)
- 7335654- [Phosphodiesterase 4 inhibitors](#)
- 7342021- [Phosphodiesterase 4 inhibitors](#)
- 7358057- [QM-7 and QT-6 cells transfected with mutant cell surface expressed channel receptors and assays using the transfected cells](#)
- 7396833- [Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof](#)
- 7405230- [Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs](#)
- 7429664- [Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof](#)
- 7432266- [Phosphodiesterase 4 inhibitors](#)
- 7495017- [Phosphodiesterase 4 inhibitors](#)
- 7576080- [Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors](#)
- 6656717- [Cyclic AMP phosphodiesterase isoforms and methods of use](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

